Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study

This publication has 9 references indexed in Scilit:

• Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT
  Frontiers in Immunology, 2019
• Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis
  Bone Marrow Transplantation, 2018
• Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab
  Blood, 2009
• Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories
  Blood, 2008
• Narrative Review: Paroxysmal Nocturnal Hemoglobinuria: The Physiology of Complement-Related Hemolytic Anemia
  Annals of Internal Medicine, 2008
• Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
  Blood, 2008
• The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
  New England Journal of Medicine, 2006
• Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy
  Cancer, 2002
• Natural History of Paroxysmal Nocturnal Hemoglobinuria
  New England Journal of Medicine, 1995